A study in Diabetic Medicine showed that adding GLP-1 receptor agonists was associated with the best rate of attaining A1C goals among type 2 diabetes patients with baseline A1C levels between 7% and 7.9%, while adding insulin led to the lowest attainment rate, compared with those whose treatment was not intensified. Researchers used a cohort of 7,389 patients and found the best goal attainment rate among those whose baseline A1C levels were between 8% and 8.9% was seen in those who received another oral antidiabetes drug, while the worst rate was seen in those whose treatment was not intensified.